share_log

HealthStream Analyst Ratings

Benzinga Analyst Ratings ·  Feb 22, 2023 08:54
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
02/22/2023 1.09% Canaccord Genuity $23 → $26 Maintains Hold
04/28/2021 -6.69% Canaccord Genuity $22 → $24 Maintains Hold
10/28/2020 -22.24% Canaccord Genuity $24 → $20 Maintains Hold
12/20/2019 Raymond James Initiates Coverage On → Market Perform
07/11/2018 Barrington Research Downgrades Outperform → Market Perform
06/14/2018 Baird Downgrades Outperform → Neutral

What is the target price for HealthStream (HSTM)?

The latest price target for HealthStream (NASDAQ: HSTM) was reported by Canaccord Genuity on February 22, 2023. The analyst firm set a price target for $26.00 expecting HSTM to rise to within 12 months (a possible 1.09% upside). 1 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for HealthStream (HSTM)?

The latest analyst rating for HealthStream (NASDAQ: HSTM) was provided by Canaccord Genuity, and HealthStream maintained their hold rating.

When is the next analyst rating going to be posted or updated for HealthStream (HSTM)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HealthStream, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HealthStream was filed on February 22, 2023 so you should expect the next rating to be made available sometime around February 22, 2024.

Is the Analyst Rating HealthStream (HSTM) correct?

While ratings are subjective and will change, the latest HealthStream (HSTM) rating was a maintained with a price target of $23.00 to $26.00. The current price HealthStream (HSTM) is trading at is $25.72, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment